Cilastatin protection against cyclosporin A-induced nephro­toxicity: clinical evidence

References

• English J, Evan A, Houghton DC, et al. Cyclosporin-induced acute renal dysfunction in the rat. Evidence of arteriolar vasoconstriction with preservation of tubular function. Transplantation 1987;44:135–41
   Google Scholar
• Grimbert P, Baron C, Fruchaud G, et al. Long-term results of a prospective randomized study comparing two immunosuppressive regimens, one with and one without CyA, in low-risk renal transplant recipients. Transplant Int 2002;15:550–5
   PubMed Web of Science ®Google Scholar
• De Mattos AM, Olyaei AJ, Bennett WM. Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future. Am J Kidney Dis 2000;35:333–46
   Google Scholar
• Rao KV. Diagnosis of renal transplant rejection in the cyclosporine era. Curr Opin Nephrol Hypertens 1992;1: 280–90
   PubMedGoogle Scholar
• Platz KP, Mueller AR, Blumhardt G, et al. Nephrotoxicity following orthotopic liver transplantation. A comparison between cyclosporine and FK506. Transplantation 1994;58: 170–8
   PubMed Web of Science ®Google Scholar
• Goldstein DJ, Zuech N, Sehgal V, et al. Cyclosporine-associated end-stage nephropathy after cardiac transplantation: incidence and progression. Transplantation 1997;63:664–8
   PubMed Web of Science ®Google Scholar
• Sido B, Hammer C, Mraz W, et al. Nephroprotective effect of imipenem/cilastatin in reducing cyclosporine toxicity. Transplant Proc 1987;1:1755–8
   Google Scholar
• Kahan FM, Kropp H, Sundelof JG, et al. Thienamycin: development of imipenem–cilastatin. J Antimicrob Chemother 1983;12:1–35
   PubMed Web of Science ®Google Scholar
• Hammer C, Thies JC, Mraz W, et al. Reduction of cyclosporin (CyA) nephrotoxicity by imipenem/cilastatin after kidney transplantation in rats. Transplant Proc 1989;21:931
   PubMed Web of Science ®Google Scholar
• Markewitz A, Hammer C, Pfeiffer M, et al. Reduction of cyclosporin-induced nephrotoxicity by cilastatin following clinical heart transplantation. Transplantation 1994;57:865–70
   PubMed Web of Science ®Google Scholar
• Carmellini M, Frosini F, Filipponi F, et al. Effect of cilastatin on cyclosporine-induced acute nephrotoxicity in kidney transplant recipients. Transplantation 1997;64:164–6
   PubMed Web of Science ®Google Scholar
• Carmellini M, Matteucci E, Boggi U, et al. Imipenem/cilastatin reduces cyclosporin-induced tubular damage in kidney transplant recipients. Transplant Proc 1998;30:2034–5
   PubMed Web of Science ®Google Scholar
• Baghaie A, Bayat M, Abobo C, et al. The effect of imipenem/ cilastatin on acute cyclosporine nephrotoxicity in heart/lung transplant patients. Crit Care Med 1995;23:A241
   Google Scholar
• Gruss E, Tomas JF, Bernis C, et al. Nephroprotective effect of cilastatin in allogeneic bone marrow transplantation. Results from a retrospective analysis. Bone Marrow Transplant 1996;18:761–5
   Google Scholar
• Nakamura T, Kokuryo T, Hashimoto Y, et al. Effects of fosfomycin and imipenem/cilastatin on the nephrotoxicity of vancomycin and cisplatin in rats. J Pharm Pharmacol 1999;51:227–32
   PubMed Web of Science ®Google Scholar
• Toyoguchi T, Takahashi S, Hosoya J, et al. Nephrotoxicity of vancomycin and drug interaction study with cilastatin in rabbits. Antimicrob Agents Chemother 1997;41:1985–90
   PubMed Web of Science ®Google Scholar
• Pérez M, Castilla M, Torres AM, et al. Inhibition of brush border dipeptidase with cilastatin reduces toxic accumulation of cyclosporin A in kidney proximal tubule epithelial cells. Nephrol Dial Transplant 2004;19:2445–55
   Google Scholar
• Parkin ET, Turner AJ, Hooper NM. Differential effects of glycosphingolipids on the detergent insolubility of the glycosylphosphatidylinositol-anchored membrane dipeptidase. Biochem J 2001;358:209–16
   Google Scholar
• Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719–48
   PubMed Web of Science ®Google Scholar
• Yusuf S, Peto R, Lewis J, et al. Beta blockade during and after myocardial infarction: an overview of randomized trials. Prog Cardiovasc Dis 1985;27:335–71
   PubMed Web of Science ®Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177–88
   PubMed Web of Science ®Google Scholar
• Berlin JA, Laird NM, Sacks HS, et al. A comparison of statistical methods for combining event rates from clinical trials. Stat Med 1989;8:141–51
   PubMed Web of Science ®Google Scholar
• Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088–101
   PubMed Web of Science ®Google Scholar
• Galbraith RF. A note on graphical presentation of estimated odds ratios from several clinical trials. Stat Med 1988;7:889–94
   PubMed Web of Science ®Google Scholar
• Hortelano S, Castilla M, Torres AM, et al. Potentiation by nitric oxide of cyclosporin A and FK506-induced apoptosis in renal proximal tubule cells. J Am Soc Nephrol. 2000;11:2315–23
   PubMed Web of Science ®Google Scholar
• Sack K, Herhahn J, Marre R, et al. Renal tolerance of imipenem cilastatin and other beta-lactam antibiotics in rats. Infection 1985;13:S156–60
   PubMed Web of Science ®Google Scholar
• Yee GC. Pharmacokinetic interactions between cyclosporine and other drugs. Transplant Proc 1990;22:1203–07
   PubMed Web of Science ®Google Scholar